ReviewIndian journal of orthopaedics2025
The Role of Intrawound Vancomycin Powder in Reducing Surgical Site Infections in Orthopedic Surgery: A Comprehensive Narrative Review of Its Efficacy, Safety, and Applications.
Review in Indian journal of orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intrawound vancomycin powder (IVP) has emerged as a promising adjunctive strategy for reducing surgical-site infections (SSIs) in orthopedic procedures. Its application spans various surgical contexts, including spine surgery, joint arthroplasty, trauma, sports surgery, and tumor-related interventions. Objective: This narrative review aims to synthesize current evidence on the efficacy, safety, and optimal application of IVP across orthopedic subspecialties. Methods: A comprehensive literature review was conducted to evaluate the outcomes of IVP use in orthopedic surgery. Relevant studies were identified and analyzed for infection rates, safety, dosing, and complications. Results: Numerous studies report reduced SSI rates with IVP, particularly in high-risk procedures. However, findings remain mixed, with some studies citing inconsistent efficacy and concerns about bacterial resistance, wound complications, and delayed healing. IVP achieves high local antibiotic concentrations with minimal systemic absorption and is generally well tolerated. Common doses range from 1 to 2 g, though optimal dosing remains unstandardized. Adverse effects are rare but include hypersensitivity and altered microbial flora. Conclusion: While IVP shows potential as an effective adjunct to prevent SSIs in orthopedic surgery, especially in high-risk cases, definitive conclusions are limited by heterogeneous data. Further high-quality randomized controlled trials are necessary to establish standardized protocols, assess long-term safety, and guide clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.